Clinical trials data
Stop-Signal Task in substance use and addiction trials: 92 registered studies
Every registered substance use and addiction study on ClinicalTrials.gov that names the Stop-Signal Task in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered substance use and addiction studies name it in an outcome measure
- 92
- Name it in a primary outcome, 46%
- 42 of 92
Tests named in the same studies
- 1
Cue Reactivity Task16 studies, 10 as a primary outcome
- 2
N-Back Task12 studies, 8 as a primary outcome
- 3
Balloon Risk11 studies, 4 as a primary outcome
- 4
Delay Discounting11 studies, 2 as a primary outcome
- 5
Stroop Color-Word Test10 studies, 5 as a primary outcome
- 6
Verbal Learning9 studies, 5 as a primary outcome
- 7
Monetary Incentive Delay6 studies, 3 as a primary outcome
- 8
Trail Making Test6 studies, 2 as a primary outcome
- 9
Go/No-Go Task5 studies, 4 as a primary outcome
- 10
Digit Span Test5 studies, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 2 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 2 | 1 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 2 | 0 |
| 2015 | 3 | 1 |
| 2016 | 8 | 4 |
| 2017 | 5 | 3 |
| 2018 | 8 | 3 |
| 2019 | 16 | 6 |
| 2020 | 7 | 6 |
| 2021 | 7 | 6 |
| 2022 | 4 | 2 |
| 2023 | 8 | 5 |
| 2024 | 7 | 2 |
| 2025 | 5 | 1 |
| 2026 | 6 | 1 |
Phases and study sizes
By phase
- Early phase 14 studies, 2 as a primary outcome
- Phase 14 studies, 2 as a primary outcome
- Phase 1/22 studies, 1 as a primary outcome
- Phase 210 studies, 5 as a primary outcome
- Phase 43 studies, 0 as a primary outcome
- Not applicable60 studies, 25 as a primary outcome
- Observational9 studies, 7 as a primary outcome
Participants per study
- Not applicable83 median, 37 to 120
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Not applicable | 60 | 83 | 37 to 120 |
When substance use and addiction trials measure it
Latest time point of each outcome
- Within a day13 outcomes, 9 as a primary outcome
- Up to 4 weeks37 outcomes, 15 as a primary outcome
- 1 to 3 months18 outcomes, 8 as a primary outcome
- 3 to 6 months6 outcomes, 2 as a primary outcome
- 6 to 12 months5 outcomes, 1 as a primary outcome
- 1 to 2 years1 outcomes, 1 as a primary outcome
- Over 2 years2 outcomes, 0 as a primary outcome
- No duration given10 outcomes, 6 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
82 of the 92 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting17 studies, 5 as a primary outcome
- Not yet recruiting3 studies, 0 as a primary outcome
- Active, not recruiting2 studies, 0 as a primary outcome
- Completed48 studies, 27 as a primary outcome
- Stopped early7 studies, 3 as a primary outcome
- Status unknown15 studies, 7 as a primary outcome
What they test
- Behavioral34 studies, 20 as a primary outcome
- Drug26 studies, 13 as a primary outcome
- Device23 studies, 4 as a primary outcome
- Dietary supplement2 studies, 1 as a primary outcome
- Procedure2 studies, 0 as a primary outcome
- Diagnostic test2 studies, 2 as a primary outcome
- Biological1 studies, 1 as a primary outcome
- Other11 studies, 4 as a primary outcome
- None given3 studies, 3 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States36 studies, 20 as a primary outcome
- China17 studies, 3 as a primary outcome
- Germany11 studies, 9 as a primary outcome
- Belgium3 studies, 1 as a primary outcome
- France3 studies, 1 as a primary outcome
- Netherlands3 studies, 0 as a primary outcome
- Spain2 studies, 1 as a primary outcome
- Switzerland2 studies, 1 as a primary outcome
- United Kingdom2 studies, 2 as a primary outcome
- Canada1 studies, 0 as a primary outcome
- Mexico1 studies, 1 as a primary outcome
- Norway1 studies, 0 as a primary outcome
17 countries in all. A study with sites in several counts in each; 5 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed substance use and addiction studies that name the Stop-Signal Task: 22 of 48, 46%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed substance use and addiction studies that name the Stop-Signal Task | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 5, 10% | 776, 10% |
| Results on ClinicalTrials.gov only | 6, 13% | 1,139, 14% |
| A results paper only | 11, 23% | 1,711, 22% |
| Neither | 26, 54% | 4,327, 54% |
The 92 studies
92 studies match. 42 name the Stop-Signal Task in a primary outcome. Median size 74 participants. Median time to the primary outcome: 4 weeks.
Loading 92 studies; the filters turn on when they arrive.
2026 is partly planned starts.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 2 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 2 | 1 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 2 | 0 |
| 2015 | 3 | 1 |
| 2016 | 8 | 4 |
| 2017 | 5 | 3 |
| 2018 | 8 | 3 |
| 2019 | 16 | 6 |
| 2020 | 7 | 6 |
| 2021 | 7 | 6 |
| 2022 | 4 | 2 |
| 2023 | 8 | 5 |
| 2024 | 7 | 2 |
| 2025 | 5 | 1 |
| 2026 | 6 | 1 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 2, other 90. Interventional 83, observational 9.
As a primary outcomeSecondary or other outcomeThe Stop-Signal Task
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07843615 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07802223 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants50 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07775807 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants5 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07417059 | Start2025 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants21 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07227545 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants18 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07154160 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants21 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06977178 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction, Anxiety, PTSD and OCD | Participants180 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06957392 | Start2026 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06867224 | Start2025 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants40 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT06798324 | Start2025 | PhasePhase 4 | ConditionsSubstance use and addiction | Participants160 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06759051 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants180 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06457230 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06454474 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants21 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06387719 | Start2023 | PhaseObservational | ConditionsObesity and diabetes, Substance use and addiction | Participants102 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06346353 | Start2024 | PhaseObservational | ConditionsDepression and bipolar disorder, Substance use and addiction, Anxiety, PTSD and OCD | Participants756 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06326684 | Start2024 | PhaseEarly phase 1 | ConditionsSubstance use and addiction | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06292156 | Start2023 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants68 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06242704 | Start2024 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants72 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06165198 | Start2023 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants9 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06105853 | Start2023 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06090422 | Start2025 | PhasePhase 1/2 | ConditionsDepression and bipolar disorder, Substance use and addiction | Participants34 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06077292 | Start2025 | PhaseNot applicable | ConditionsSubstance use and addiction | Participants110 | Lead sponsorOther | StatusStopped early | Library tests named
|
| NCT05992272 | Start2020 | PhaseObservational | ConditionsSubstance use and addiction | Participants300 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05946083 | Start2023 | PhasePhase 2 | ConditionsSubstance use and addiction | Participants82 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05899660 | Start2023 | PhaseNot applicable | ConditionsDepression and bipolar disorder, Substance use and addiction, Anxiety, PTSD and OCD | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
Questions, answered from the data
How many substance use and addiction trials use the Stop-Signal Task?
92 registered substance use and addiction studies on ClinicalTrials.gov name it in an outcome measure, 42 of them in a primary outcome: 10% of the condition's 895 studies with a cognitive outcome, against 2% of all of them. It is the 3rd most named test in substance use and addiction trials.
Which tests do substance use and addiction trials use with the Stop-Signal Task?
The Cue Reactivity Task (16 studies), the N-Back Task (12 studies) and Balloon Risk (11 studies).
When do substance use and addiction trials measure the Stop-Signal Task?
Half of the primary outcomes that name the Stop-Signal Task are measured within 4 weeks of the start, and the middle half from 5 days to 8 weeks. 36 primary outcomes give a duration.
How many completed substance use and addiction trials that use the Stop-Signal Task have reported results?
22 of the 48 completed studies that name it, 46%, have reported results: 11 posted them on ClinicalTrials.gov, 16 have a results paper linked to the registry record, and 5 did both. The other 26 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run the Stop-Signal Task in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.